Radius Health, Inc. (RDUS) Price Target Cut to $31.00 by Analysts at Jefferies Group LLC

Radius Health, Inc. (NASDAQ:RDUS) had its target price cut by Jefferies Group LLC from $38.00 to $31.00 in a report issued on Friday. The firm currently has a “hold” rating on the biopharmaceutical company’s stock. Jefferies Group LLC’s price target would suggest a potential upside of 7.04% from the company’s previous close.

Several other analysts have also issued reports on RDUS. BidaskClub lowered shares of Radius Health from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Canaccord Genuity set a $85.00 price target on shares of Radius Health and gave the stock a “buy” rating in a research report on Monday, July 17th. Cantor Fitzgerald set a $65.00 target price on shares of Radius Health and gave the company a “buy” rating in a research report on Monday, July 17th. Zacks Investment Research upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Finally, Maxim Group reiterated a “positive” rating on shares of Radius Health in a research report on Friday, September 29th. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. Radius Health currently has a consensus rating of “Hold” and an average price target of $51.00.

Shares of Radius Health (NASDAQ RDUS) traded down $1.18 during midday trading on Friday, reaching $29.67. 2,136,509 shares of the company were exchanged, compared to its average volume of 954,239.

Radius Health (NASDAQ:RDUS) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.03). The company had revenue of $13.50 million for the quarter, compared to analyst estimates of $6.90 million. During the same quarter in the previous year, the firm earned ($1.07) EPS. equities research analysts forecast that Radius Health will post -5.28 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/11/03/radius-health-inc-rdus-price-target-cut-to-31-00-by-analysts-at-jefferies-group-llc.html.

In related news, major shareholder Growth N. V. Biotech bought 150,000 shares of the company’s stock in a transaction on Thursday, August 10th. The stock was bought at an average cost of $34.97 per share, with a total value of $5,245,500.00. Following the completion of the purchase, the insider now owns 5,113,799 shares in the company, valued at approximately $178,829,551.03. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Jesper Hoiland bought 6,100 shares of the company’s stock in a transaction on Friday, September 15th. The stock was bought at an average cost of $32.72 per share, with a total value of $199,592.00. Following the completion of the purchase, the insider now owns 6,100 shares of the company’s stock, valued at approximately $199,592. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 519,100 shares of company stock valued at $17,970,882. Insiders own 15.00% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the business. BB Biotech AG raised its stake in shares of Radius Health by 11.0% in the second quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock worth $227,905,000 after acquiring an additional 498,400 shares during the last quarter. Farallon Capital Management LLC raised its stake in shares of Radius Health by 18.3% in the second quarter. Farallon Capital Management LLC now owns 3,686,300 shares of the biopharmaceutical company’s stock worth $166,731,000 after acquiring an additional 569,300 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Radius Health by 4.5% in the second quarter. Vanguard Group Inc. now owns 3,145,717 shares of the biopharmaceutical company’s stock worth $142,281,000 after acquiring an additional 135,071 shares during the last quarter. BlackRock Inc. raised its stake in shares of Radius Health by 10.0% in the second quarter. BlackRock Inc. now owns 2,893,641 shares of the biopharmaceutical company’s stock worth $130,881,000 after acquiring an additional 262,896 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Radius Health by 12.9% during the second quarter. State Street Corp now owns 1,867,531 shares of the biopharmaceutical company’s stock worth $84,473,000 after buying an additional 213,399 shares during the last quarter.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

What are top analysts saying about Radius Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Radius Health Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit